associated with CV events increased by 73% (40.7% v 70.6%), largely due to a 600% (0.3% v 2.1%) increase in acute myocardial infarction. Lastly, negative clinical outcomes associated with renal toxicity increased by 433% (1.5% v 8.0%), with a 740% (9.5% v 4.2%) increase in acute renal failure being the most substantial.

Conclusion: These findings suggest that prescribing of NSAIDs among OA patients is associated with an increase in negative clinical outcomes. This suggests that new treatment options other than NSAIDs should be evaluated.

References:

Disclosure of Interests: Stuart Silverman Consultant of: Pfizer and Eli Lilly for this project. Speakers bureau: Amgen, Radius. James Rice Consultant of: Pfizer and Eli Lilly have funded this project. Alan White Consultant of: Pfizer and Eli Lilly have funded this project. Nguyen Le Consultant of: Pfizer and Eli Lilly have funded this project. Michael Somma Consultant of: Eli Lilly and Pfizer have funded this project. Craig Beck Shareholder of: Pfizer. Employee of: Pfizer. Rebecca Robinson Shareholder of: Eli Lilly. Employee of: Pfizer. Patricia Schepman Shareholder of: Pfizer. Employee of: Pfizer. Alan Rice Consultant of: Pfizer and Eli Lilly have funded this project. Stuart Silverman Consultant of: Pfizer and Eli Lilly have funded this project. O. Sleglova Consultant of: Pfizer.

DOI: 10.1136/annrheumdis-2020-eular.3716

O. Sleglova1, O. Růžičková1, K. Pavelka1, L. Šenolt2. 1Institute of Rheumatology Prague, Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic; 2Institute of Rheumatology, Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic

Background: Hand osteoarthritis (HOA) is a common and frequent cause of pain. HOA is a heterogeneous group of disorders with two main subsets including non-erosive and erosive disease. Few studies demonstrated inflammatory-ultrasound changes and more severe clinical symptoms in patients with erosive compared with non-erosive disease, however the results are inconsistent.

Objectives: The aim of this study was to evaluate progression of pain, stiffness, physical impairment and ultrasound features in patients with erosive and non-erosive HOA in a three years longitudinal study.

Methods: Consecutive patients with symptomatic HOA fulfilling the American College of Rheumatology (ACR) criteria were included in this study. Joint pain and swelling were assessed. Patients reported joint pain on 100mm visual analogue scale (VAS). Pain, joint stiffness and disability were assessed by the Australian/Canadian OA hand index (AUSCAN). Erosive disease was defined by at least one erosive interphalangeal joint. Synovial hypertrophy and power Doppler signal (PDS) were scored with ultrasound. Synovitis was graded on a scale of 0–3 and osteophytes were defined as cortical protrusions seen in two planes. Patients were examined at baseline and at the first, second and third year of follow-up.

Results: Altogether, 151 patients (16 male) with symptomatic nodal HOA were included in this study and followed between April 2012 and January 2020. Out of these patients, 84 (4 male) had erosive disease. The disease duration (p<0.05) was higher in patients with erosive compared with non-erosive disease. Pain reported on VAS was significantly higher (p<0.01) in patients with erosive compared with non-erosive disease at baseline. Progression of pain after the third year of follow up was significantly higher in patients with erosive disease (p<0.01). The number of painful and clinically swollen joints (p<0.05) was significantly higher in patients with erosive compared with non-erosive disease at baseline. It fluctuated over the second and third year of follow up, but it still remained statistically higher (p<0.01) at the third year of follow up in patients with erosive disease.

According to the AUSCAN, patients with erosive compared with non-erosive disease had more pain (p<0.01) and stiffness (p<0.01) at baseline. Pain (p<0.05), stiffness and also function (p<0.05) worsened in patients with erosive compared with non-erosive disease at third year of follow up.

Conclusion: The main aim of this study was to investigate possible differences in pain, stiffness, physical impairment and ultrasound features in patients with erosive and non-erosive HOA in a three years longitudinal study. These findings suggest that non-erosive HOA is less severe compared with erosive HOA. Larger studies are needed to confirm these results.

References:

Acknowledgments: This work was supported by the project MCR 023728 and went with the COST Action R3-10015.

Disclosure of Interests: Olga Sleglova: None declared. Oleg Ruzickov: None declared. Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egle, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egls, Roche, UCB, Medac, Pfizer, Biogen, Ladislav Šenolt: None declared.

DOI: 10.1136/annrheumdis-2020-eular.2055

P. Steen Petterson1,2, T. Neogi3, K. Magnusson1, B. Slätow-Kristensen1, H. B. Hammer4, T. Uhlig5, T. K. Kvien1, K. J. Haugen1. 1Diakonhjemmet Hospital, Rheumatology, Oslo, Norway; 2University of Oslo, Faculty of Medicine, Oslo, Norway; 3Boston University School of Medicine, Rheumatology, Boston, United States of America

Background: Pressure pain threshold (PPT) is a measure of pain sensatization; altered pain mechanisms in the peripheral and/or central nervous system causing increased pain sensatization. PPT testing may be a useful tool to classify pain phenotypes but requires special equipment not available in the clinic. The Doyle index (DI) is a clinical measure of joint tenderness upon palpation. It is considered as an outcome measure of pain and disease activity in hand OA and is a potential alternative to PPT. It is unclear if joint tenderness is related to pain sensitization, as joint tenderness could reflect pure nociceptive pain without sensitization.

Objectives: Using data from the Nor-Hand study we will explore how DI performs as a measure of pain sensitization in hand OA by examining associations and agreements between DI and PPT at joint level, and correlations between PPT values and DI sum score at person level.

Methods: PPT was tested with a hand-held algometer (FPX25, 1cm² flat rubber tip) at the dorsal side of the most painfull DIP/IP and a non-painfull DIP/IP joint (local PPTs) and left radioular joint and mid-portions of the trapezius and tibialis anterior muscle (remote PPTs). Low local PPTs indicate peripheral and/or central sensitization, while low remote PPTs indicate central sensitization. According to DI, tenderness in the bilateral thumb base and finger joints were graded by a rheumatologist by pressing on the lateral joint margins: 0=no pain, 1=patient complains of pain, 2=patient complains of pain and winces, 3=patient complains of pain, winces and withdraws joint. We examined whether increasing DI was associated with local PPT using mixed models. To assess agreement between DI and PPT, we categorized PPT of the painful finger joints into a semi-quantitative scale with the same number of categories (n=4) as DI. We identified the cut-offs for the PPT categories that maximized the agreement (weighted kappa) with DI. Finally, we examined Spearman’s correlations between DI sum score [range 0-90] and PPTs of local and remote sites.

Results: The majority of the 285 eligible participants were women (88%) and mean (SD) age was 61 (6) years. Joints with high DI had lower PPT values (Figure 1). We found a linear association of lower PPT with increasing DI for all joints combined (beta -0.7, 95% CI -0.8, -0.6). Similar results were found for the painful joints (beta -0.8, 95% CI -1.0, -0.6), but weaker for non-painful joints (beta -0.5, 95% CI -1.0, 0.0) where few joints had DI grade 2-3 (Figure 1). The analyses on maximized agreement between DI and the PPT categories gave a weighted kappa equal to 0.32 (Table). Median (IQR) DI sum score was 9 (5, 15). We found weak inverse correlations between DI sum score and PPT at local (painful finger: p=-0.24 (95% CI -0.32, -0.16), non-painful finger: p=-0.22 (95% CI -0.29, -0.11) and remote sites (radialulnar joint: p=-0.17 (95% CI -0.29, -0.08), trapezius: p=-0.25 (95% CI -0.36, -0.14), tibialis anterior: p=-0.20 (95% CI -0.31, -0.09).

Conclusion: The DI is associated with lower PPT at painful finger joints. Large variance of PPT within each DI grade resulted in fair agreement. DI of non-painful joints.
finger joints was weakly associated with PPT, demonstrating that the DI does not differentiate pain sensitization in joints without ongoing nociceptive pain. Correlations between DI sum score and PPT of remote sites were also weak. The two measures seem to assess different constructs and are therefore not interchangeable.

The table below shows the cross tabulation of DI with the best PPT categorization of painful finger joints. Cells = joint count.

<table>
<thead>
<tr>
<th>PPT categories</th>
<th>0 (range, kg/cm²)</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>4.7-12</td>
<td>32</td>
<td>21</td>
<td>11</td>
</tr>
<tr>
<td>1</td>
<td>3.4-4.6</td>
<td>29</td>
<td>31</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>2.1-3.3</td>
<td>22</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>0-2.0</td>
<td>15</td>
<td>7</td>
<td>2</td>
</tr>
</tbody>
</table>

PPT categories 0-3 (i.e. decreasing PPT) represent the categorization that gave maximized agreement with DI (weighted kappa = 0.32).

**Disclosure of Interests:** Pernille Steen Petersen: None declared, Tuhina Neogi Grant/research support from: Pfizer/Lilly, Consultant of: Pfizer/Lilly, EMD-Merck Serono, Novartis, Karin Magnusson: None declared, Barbara Slatkowsky-Chris- tensen: None declared, Hilde Beren Hammer Consultant of: Has received fees as consultant from Roche, AbbVie and Novartis., Speakers bureau: Has received fees for speaking from AbbVie, EMS, Pfizer, UCB, Roche, MSD and Novartis, Till Uhlig Consultant of: Lilly, Pfizer, Speakers bureau: Grünenthal, Novartis, Tore K. Kvien Grant/research support from: Received grants from Abbvie, Hospira/Pfizer, MSD and Roche (not relevant for this abstract.), Consultant of: Have received personal fees from Abbvie, Biogen, BMS, Celtrion, Eli Lilly, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract.), Paid instructor for: Have received personal fees from Abbvie, Biogen, BMS, Celtrion, Eli Lilly, Hospira/Pfizer, MSD, Novartis, Orion Pharma, Roche, Sandoz, UCB, Sanofi and Mylan (not relevant for this abstract.), Ida K. Haugen: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.762

---

**FR10426**

**EMOTIONAL COMPONENTS AND INFLAMMATION ARE HIGHLY RELEVANT IN PAIN REPORTED BY KNEE OSTEOARTHRITIC PATIENTS**

L. Tío1, F. Castro1,2, S. Tassani3, M. Á. González-Ballester1,4, J. Noailly5, J.C. Monllau1,5, J. Monfort1,2.

**Background:** Osteoarthritis (OA) is a leading cause of disability in elderly and the most frequent form is knee OA (KOA) (1). Pain is the principal symptom that leads patients to visit clinicians, and it is the main reason, together with functionality, for patients to undergo a total knee replacement (TKR) after apparently unsuccessful conservative (CNV) treatments (2). It is well-known that there is a poor correlation between the radiographic severity (based on Kellgren & Lawrence (KL) score) and the reported pain (3), so other variables may be responsible for the intensity of pain.

**Objectives:** Identifying the leading causes of pain in each patient would improve the management of the disease. In this study we aim to investigate the role of emotional components, nociception process and inflammation in treatment decision, as a global measure of pain suffered by KOA patients, taking into account sex, age and BMI.

**Methods:** KOA patients, carefully selected to be idiopathic, graded 2-3 in KL, were recruited at Hospital del Mar. The following variables were recorded: WOMAC, Hospital Anxiety and Depression Scale (HAD), Pain Catastrophizing Scale (PCS), tender points (TP) (measure with a pressure algometer at points defined in the Arendt-Nielsen extended peripatellar map), synovial hypertrophy (SH) and effusion (SE) (measure by ultrasounds), and PCR and ESR serum levels. Patients were classified according to 4 factors: treatment (CNV/TKR), sex, age (60-67/68-75) and BMI (<30/>30). All groups were balanced. Multivariate and correlations analysis were performed.

**Results:** Eighty-seven patients have been recruited. Patients from the TKR group present significant higher WOMAC (p=0.000), PCS (p=0.002) and SE (p= 0.038) values than CNV ones, without interaction with the other factors, except for SE, that presents interaction with BMI (Fig. 1). Women reported significant upper WOMAC (p=0.001) and HAD rates (p=0.020), but also higher number of TP and ESR levels (p= 0.000 and 0.002, respectively). The level of sensitization was significantly higher in women than in men (p=0.000). Several significant correlations were found, mainly between WOMAC and emotional components, as well as between TP and WOMAC, PCS, and inflammation markers (Table 1).

**Conclusion:** PCS is an emotional component that could explain in part the lack of correlation between joint status and patient’s symptomatology. Working